Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 6/20 | 0.73 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.70 |
| ▸ | HTR3A | P46098 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8947433 | 1.00 | HTR4 (0.73) | HTR4TMEM97SIGMAR1HTR3A | |
| SCHEMBL30139058 | 1.00 | HTR4 (0.73) | HTR4TMEM97SIGMAR1HTR3A | |
| SCHEMBL30428794 | 1.00 | HTR4 (0.73) | HTR4TMEM97SIGMAR1HTR3A | |
| Hydrochloric Acid SCHEMBL29384867 | 0.99 | HTR4 (0.72) | HTR4TMEM97SIGMAR1HTR3A | |
| Hydrochloric Acid SCHEMBL7637431 | 0.99 | HTR4 (0.72) | HTR4TMEM97SIGMAR1HTR3A | |
| Hydrochloric Acid SCHEMBL7634797 | 0.99 | HTR4 (0.72) | HTR4TMEM97SIGMAR1HTR3A | |
| Hydrochloric Acid SCHEMBL10322633 | 0.99 | HTR4 (0.72) | HTR4TMEM97SIGMAR1HTR3A | |
| SCHEMBL13616746 | 0.87 | HTR4 (0.63) | HTR4TMEM97SIGMAR1HTR3A | |
| SCHEMBL8947426 | 0.86 | HTR4 (0.74) | HTR4TMEM97SIGMAR1HTR3A | |
| SCHEMBL7340846 | 0.86 | HTR4 (0.74) | HTR4TMEM97SIGMAR1HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230147744-A1 | METHODS TO ENRICH ENTEROENDOCRINE CELLS AND THEIR SUBTYPES IN THE CONTIGUOUS, INTESTINAL MONOLAYER SYSTEMS | UNIVERSITY OF WASHINGTON | 2023-05-11 | — | — | US | claimed |
| EP-4126218-A1 | METHODS TO ENRICH ENTEROENDOCRINE CELLS AND THEIR SUBTYPES IN THE CONTIGUOUS, INTESTINAL MONOLAYER SYSTEMS | The University of North Carolina at Chapel Hill (US) | 2023-02-08 | — | — | EP | claimed |
| EP-0523013-B1 | Use of benzimidazoline-2-oxo-1-carboxylic acid derivatives in the treatment of organic mental diseases | BOEHRINGER INGELHEIM ITALIA (IT) | 1994-12-21 | — | — | EP | claimed |
| EP-0523013-A2 | Use of benzimidazoline-2-oxo-1-carboxylic acid derivatives in the treatment of organic mental diseases | BOEHRINGER INGELHEIM ITALIA S.p.A. (IT) | 1993-01-13 | — | — | EP | claimed |
| EP-4706758-A2 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250213564-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER NEUROGENERATIVE DISEASE | THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20240325487-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2024-10-03 | — | — | US | disclosed |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| EP-3884935-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20230147744-A1 | METHODS TO ENRICH ENTEROENDOCRINE CELLS AND THEIR SUBTYPES IN THE CONTIGUOUS, INTESTINAL MONOLAYER SYSTEMS | UNIVERSITY OF WASHINGTON | 2023-05-11 | — | — | US | disclosed |
| US-20230121608-A1 | Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety- Like Behavior | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-04-20 | — | — | US | disclosed |
| WO-2006119295-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006119329-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2005021539-A1 | BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER JAPAN, INC. (JP) | 2005-03-10 | — | — | WO | disclosed |
| US-5552408-A | Benzimidazoline-2-oxo-1-carboxylic acid derivatives useful as 5-ht receptor antagonists | BOEHRINGER INGELHEIM ITALIA S.P.A. (IT) | 1996-09-03 | — | — | US | disclosed |
| EP-0523013-B1 | Use of benzimidazoline-2-oxo-1-carboxylic acid derivatives in the treatment of organic mental diseases | BOEHRINGER INGELHEIM ITALIA (IT) | 1994-12-21 | — | — | EP | disclosed |
| US-5358954-A | Antiserotonine agent, antiemetic, gastrointestinal disorders | BOEHRINGER INGELHEIM ITALIA (IT) | 1994-10-25 | — | — | US | disclosed |
| US-5223511-A | Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists | BOEHRINGER INGELHEIM ITALIA S.P.A. (IT) | 1993-06-29 | — | — | US | disclosed |
| EP-0523013-A2 | Use of benzimidazoline-2-oxo-1-carboxylic acid derivatives in the treatment of organic mental diseases | BOEHRINGER INGELHEIM ITALIA S.p.A. (IT) | 1993-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325487-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | HTR4 1928/4885TMEM97 933/4885SIGMAR1 1242/4885 |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | SLC34A3, SLC34A2, SLC34A1 | HTR4 1928/4885TMEM97 933/4885SIGMAR1 1242/4885 |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | HTR4 3153/4885TMEM97 1572/4885SIGMAR1 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.